IL17A and psoriatic arthritis: Current inhibitors of IL-17A, including anti-IL-17A monoclonal antibodies seckinumab, ixekizumab, and bimekizumab, have been approved for the treatment of autoimmune diseases such as psoriatic arthritis (25) and ankylosing spondylitis (26).